MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
MediWound Ltd. - Ordinary Shares (MDWD)
Last mediwound ltd. - ordinary shares earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.mediwound.com/press-releases
Company Research
Source: GlobeNewswire
EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million EIC Funding Strengthen Cash Runway to Profitability NexoBrid Product Revenue Meets Expectations; Demand Exceeds Capacity as New Manufacturing Facility Commissioning Underway Conference Call Today, November 26 at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 26, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update. “We made great headway toward our objectives this quarter, achieving a major milestone with NexoBrid approval for pediatric use in the U.S.,” said Ofer Gonen, Chief Executive Officer of MediWound. “With the upcoming launch of the Phase 3 trial for EscharEx in venou
Show less
Read more
Impact Snapshot
Event Time:
MDWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDWD alerts
High impacting MediWound Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MDWD
News
- MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025 [Yahoo! Finance]Yahoo! Finance
- MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025GlobeNewswire
- MediWound Ltd. (NASDAQ: MDWD) had its price target lowered by analysts at HC Wainwright from $28.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- MediWound Ltd (MDWD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]Yahoo! Finance
- MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
MDWD
Earnings
- 11/26/24 - Miss
MDWD
Analyst Actions
- 10/11/24 - HC Wainwright
MDWD
Sec Filings
- 12/19/24 - Form 6-K
- 12/16/24 - Form 6-K
- 11/26/24 - Form 6-K
- MDWD's page on the SEC website